Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience.

被引：0
|
作者：
O'Connor, Owen A.
Hamlin, P. A.
Gerecitano, J.
Portlock, C. S.
Noy, A.
Moskowitz, C.
Straus, D. J.
Sarasohn, D.
Dumetrescu, O.
Pappanicolou, J.
Neylon, E.
Zelenetz, A. D.
Saunders, M. E.
Mould, D. R.
Fleischer, M.
Sirotnak, F.
Horwitz, S. M.
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Allos Therapeut Inc, Westminster, CO USA
[3] Project Res, Phoenix, AZ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
400
引用
收藏
页码：122A / 123A
页数：2
相关论文
共 50 条
  • [31] Dose-Adjusted EPOCH Chemotherapy for Untreated Peripheral T-Cell Lymphomas: Multicenter Phase II Trial of West-Jhog PTCL0707
    Maeda, Yoshinobu
    Nishimori, Hisakazu
    Hiramatsu, Yasushi
    Yoshida, Isao
    Uno, Masatoshi
    Masaki, Yasufumi
    Sunami, Kazutaka
    Masunari, Taro
    Nawa, Yuichiro
    Gomyo, Hiroshi
    Yamane, Hiromichi
    Takahashi, Tsutomu
    Yano, Tomofumi
    Takimoto, Hidetaka
    Matsuo, Keitaro
    Yoshino, Tadashi
    Tanimoto, Mitsune
    BLOOD, 2016, 128 (22)
  • [32] Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707
    Maeda, Yoshinobu
    Nishimori, Hisakazu
    Yoshida, Isao
    Hiramatsu, Yasushi
    Uno, Masatoshi
    Masaki, Yasufumi
    Sunami, Kazutaka
    Masunari, Taro
    Nawa, Yuichiro
    Yamane, Hiromichi
    Gomyo, Hiroshi
    Takahashi, Tsutomu
    Yano, Tomofumi
    Matsuo, Keitaro
    Ohshima, Koichi
    Nakamura, Shigeo
    Yoshino, Tadashi
    Tanimoto, Mitsune
    HAEMATOLOGICA, 2017, 102 (12) : 2097 - 2103
  • [33] Recombinant anti-CD22 immunotoxin BL22 induces durable complete remissions in phase I and II trials of patients with chemoresistant hairy cell leukemia.
    Kreitman, RJ
    Wilson, WH
    Stetler-Stevenson, M
    FitzGerald, DJ
    Pastan, I
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9120S - 9121S
  • [34] High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience
    Rodriguez, J
    Caballero, MD
    Gutierrez, A
    Gandarillas, M
    Sierra, J
    Lopez-Guillermo, A
    Sureda, A
    Zuazu, J
    Marin, J
    Arranz, R
    Carreras, E
    Leon, A
    de Sevilla, AF
    Miguel, JFS
    Conde, E
    HAEMATOLOGICA, 2003, 88 (12) : 1372 - 1377
  • [35] Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study
    Advani, Ranjana
    Hymes, K.
    Pohlman, B.
    Jacobsen, E.
    McDonnell, J.
    Belt, R.
    Lerner, A.
    Kim, Y.
    Mundis, R.
    Mansfield, T.
    Buhl-Jensen, P.
    Ooi, C. E.
    Duvic, M.
    Foss, F.
    BLOOD, 2007, 110 (11) : 1012A - 1012A
  • [36] PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma
    O'Connor, Owen A.
    Pro, Barbara
    Pinter-Brown, Lauren
    Popplewell, Leslie
    Barlett, Nancy
    Shustov, Andrei
    Lechowicz, Mary Jo
    Savage, Kerry J.
    Coiffier, Bertrand
    Jacobsen, Eric
    Zinzani, Pier Luigi
    Goy, Andre
    Zain, Jasmine
    Wilroy, Shannon
    Patterson, Molly
    Boyd, Adam
    Saunders, Michael E.
    Cagnoni, Pablo
    Horwitz, Steven M.
    BLOOD, 2008, 112 (11) : 103 - 103
  • [37] CHODBleo/DHAP a phase II trial of alternating non-cross resistant chemotherapy for intermediate grade peripheral T-cell non-Hodgkin's lymphoma with results at five years
    Melnyk, A
    Rodriguez, A
    Pugh, WC
    Cabanillas, F
    BLOOD, 1996, 88 (10) : 2266 - 2266
  • [38] Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma
    Stuver, Robert
    Horwitz, Steven M.
    Advani, Ranjana H.
    Vose, Julie M.
    Lee, Hun Ju
    Mehta-Shah, Neha
    Zain, Jasmine M.
    Haverkos, Bradley
    Lechowicz, Mary Jo
    Moskowitz, Alison J.
    Pham, Luu Q.
    Leyden, Elizabeth
    Ansell, Stephen M.
    Lunning, Matthew A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, : 525 - 529
  • [39] Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
    O'Connor, Owen A.
    Horwitz, Steven
    Masszi, Tamas
    Van Hoof, Achiel
    Brown, Peter
    Doorduijn, Jeannette
    Hess, Georg
    Jurczak, Wojciech
    Knoblauch, Poul
    Chawla, Shanta
    Bhat, Gajanan
    Choi, Mi Rim
    Walewski, Jan
    Savage, Kerry
    Foss, Francine
    Allen, Lee F.
    Shustov, Andrei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) : 2492 - U21
  • [40] Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma
    Pohlman, Brad
    Advani, Ranjana
    Duvic, Madeleine
    Hymes, Kenneth B.
    Intragumtornchai, Tanin
    Lekhakula, Arnuparp
    Shpilberg, Ofer
    Lerner, Adam
    Ben-Yehuda, Dina
    Beylot-Barry, Marie
    Hillen, Uwe
    Fagerberg, Jan
    Foss, Francine M.
    BLOOD, 2009, 114 (22) : 379 - 379
12345